Novo Nordisk
NVO
513 hedge funds and large institutions have $7.77B invested in Novo Nordisk in 2016 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 190 increasing their positions, 188 reducing their positions, and 53 closing their positions.
1% more repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 188
0.59% less ownership
Funds ownership: 19.15% → 18.56% (-0.59%)
3% less funds holding
Funds holding: 530 → 513 (-17)
21% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 53
25% less capital invested
Capital invested by funds: $10.4B → $7.77B (-$2.61B)
42% less funds holding in top 10
Funds holding in top 10: 24 → 14 (-10)
51% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$165M |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$92.2M |
| 3 |
Renaissance Technologies
New York
|
+$84.5M |
| 4 |
Morgan Stanley
New York
|
+$70.2M |
| 5 |
Millennium Management
New York
|
+$67.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$545M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$329M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$103M |
| 4 |
Lazard Asset Management
New York
|
-$78.6M |
| 5 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$47.6M |
NVO Hedge Fund Activity: Q3 2016 in Review
513 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2016, worth a combined $7.77B — down 25% from $10.4B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of NVO and 42 opened new positions — a net loss of 11 holders — while 188 trimmed existing stakes and 190 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $165M. The largest seller was Jennison Associates, cutting an estimated $545M.
- 513 institutional investors held Novo Nordisk (NVO) as of Q3 2016, down from 530 in Q2 2016.
- Funds reported $7.77B of Novo Nordisk stock for Q3 2016, down 25% quarter-over-quarter.
- 42 funds opened new Novo Nordisk positions in Q3 2016 and 53 closed out, a net change of -11 holders.
- The largest Novo Nordisk buyer in Q3 2016 was Loomis, Sayles & Company, an estimated $165M added.
- The largest Novo Nordisk seller in Q3 2016 was Jennison Associates, an estimated $545M sold.
Based on aggregated 13F filings for Q3 2016.